These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 19075241

  • 1. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
    Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR.
    Proc Natl Acad Sci U S A; 2008 Dec 23; 105(51):20476-81. PubMed ID: 19075241
    [Abstract] [Full Text] [Related]

  • 2. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
    Henrich TJ, Lewine NR, Lee SH, Rao SS, Berro R, Gulick RM, Moore JP, Tsibris AM, Kuritzkes DR.
    Antimicrob Agents Chemother; 2012 Apr 23; 56(4):1931-5. PubMed ID: 22252820
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AM.
    J Virol; 2012 Jan 23; 86(2):1119-28. PubMed ID: 22090117
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
    Ogert RA, Ba L, Hou Y, Buontempo C, Qiu P, Duca J, Murgolo N, Buontempo P, Ralston R, Howe JA.
    J Virol; 2009 Dec 23; 83(23):12151-63. PubMed ID: 19776131
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR.
    Antimicrob Agents Chemother; 2007 Jul 23; 51(7):2489-96. PubMed ID: 17485501
    [Abstract] [Full Text] [Related]

  • 9. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
    McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM.
    J Clin Virol; 2012 Oct 23; 55(2):134-9. PubMed ID: 22824230
    [Abstract] [Full Text] [Related]

  • 10. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
    McNicholas PM, Mann PA, Wojcik L, Qiu P, Lee E, McCarthy M, Shen J, Black TA, Strizki JM.
    J Acquir Immune Defic Syndr; 2011 Mar 01; 56(3):222-9. PubMed ID: 21209592
    [Abstract] [Full Text] [Related]

  • 11. V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.
    Wu E, Du Y, Gao X, Zhang J, Martin J, Mitreva M, Ratner L.
    J Virol; 2019 May 01; 93(9):. PubMed ID: 30787151
    [Abstract] [Full Text] [Related]

  • 12. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
    Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR.
    J Virol; 2012 Jun 01; 86(12):6416-26. PubMed ID: 22491471
    [Abstract] [Full Text] [Related]

  • 13. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
    Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM.
    Antimicrob Agents Chemother; 2005 Dec 01; 49(12):4911-9. PubMed ID: 16304152
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
    Anastassopoulou CG, Ketas TJ, Sanders RW, Klasse PJ, Moore JP.
    Virology; 2012 Jul 05; 428(2):86-97. PubMed ID: 22520838
    [Abstract] [Full Text] [Related]

  • 16. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.
    J Pharmacol Exp Ther; 2011 Jul 05; 338(1):228-39. PubMed ID: 21459966
    [Abstract] [Full Text] [Related]

  • 17. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.
    Antimicrob Agents Chemother; 2006 Oct 05; 50(10):3289-96. PubMed ID: 17005807
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
    Nakata H, Maeda K, Das D, Chang SB, Matsuda K, Rao KV, Harada S, Yoshimura K, Ghosh AK, Mitsuya H.
    Sci Rep; 2019 Mar 18; 9(1):4828. PubMed ID: 30886166
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G.
    J Infect Dis; 2008 Oct 15; 198(8):1113-22. PubMed ID: 18783318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.